While emerging biomarkers such as PCSK9, EPHX2, AOPPs, and TBARSs offer exciting prospects for improving the diagnosis, monitoring, and treatment of CKD, several limitations must be addressed to realize their full clinical potential. The gene discussed is PCSK9; the disease is chronic kidney disease.